Wells Fargo’s Protara Therapeutics TARA Stock Holding History
Bought
Maintained
Sold
Other funds holding TARA
VCIM
VCM
SCM
ACA
IHAM
ACM
Wells Fargo's TARA Position: Q1 2026 in Review
Wells Fargo reduced its Protara Therapeutics (TARA) stake by 23% in Q1 2026, selling an estimated $53.9K and leaving 30,697 shares worth $160K. The position accounts for ﹤0.01% of the portfolio, ranked #4831.
Wells Fargo first reported a position in TARA in Q2 2015 and has held it in 26 quarters since. The position peaked at $1.07M in Q1 2021. 114 funds tracked by Wall St. Rank hold TARA as of Q1 2026.
- Wells Fargo held 30,697 shares of Protara Therapeutics worth $160K as of Q1 2026.
- Wells Fargo sold 9,105 Protara Therapeutics shares in Q1 2026, an estimated $53.9K.
- Protara Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #4831 holding.
- Wells Fargo first reported a position in Protara Therapeutics in Q2 2015 and has held it in 26 quarters since.
- Wells Fargo's Protara Therapeutics position peaked at $1.07M in Q1 2021.
- 114 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2026.
Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.